News

Lilly to offer highest doses of weight-loss drug Zepbound on website
Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...
STAT2h
Lilly adds highest Zepbound doses to DTC offering
Eli Lilly is buying Verve Therapeutics, developer of gene-editing treatments for cardiovascular disease, for $1 billion plus ...
Lilly to Offer Higher Dose Versions of Weight-Loss Drugs on Website
(Reuters) -U.S. drugmaker Eli Lilly said on Monday it will offer the higher dose versions of its popular weight-loss drug ...
Eli Lilly: The Buy Case Gets Stronger (Rating Upgrade)
Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...
This Stock Just Jumped 77% After Eli Lilly Made an Agreed $1.3 Billion Bid
Verve Therapeutics stock jumped after pharmaceutical giant Eli Lilly said it is buying the gene-editing start-up for up to $1 ...
Eli Lilly’s Dividend May Be Small, But its Growth Tells a Bigger Story
Eli Lilly and Company (NYSE:LLY) may offer a modest dividend yield, but its track record of consistent payouts remains strong ...
Explore more
PharmExec22h
Lilly Launches Full Zepbound Dose Access for Obesity Through LillyDirect Self-Pay Program
Starting July 7, 2025, the two highest doses of Zepbound will be available for a flat price of $499 per month, with shipments ...
Zacks Investment Research on MSN19h
Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts
Eli Lilly (LLY) ended the recent trading session at $807.58, demonstrating a -1.44% change from the preceding day's closing price. This change lagged the S&P 500's 0.94% gain on the day. At the same ...